CN112638903B - 舒欣啶盐 - Google Patents

舒欣啶盐 Download PDF

Info

Publication number
CN112638903B
CN112638903B CN202080004796.1A CN202080004796A CN112638903B CN 112638903 B CN112638903 B CN 112638903B CN 202080004796 A CN202080004796 A CN 202080004796A CN 112638903 B CN112638903 B CN 112638903B
Authority
CN
China
Prior art keywords
sulcardine
salt
crystalline
peaks
xrpd pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080004796.1A
Other languages
English (en)
Chinese (zh)
Other versions
CN112638903A (zh
Inventor
苏珊妮·J·罗马诺
海莉·安·里斯
约瑟夫·爱德华·戈登·本森
莎拉·柯林斯
加里·T·艾略特
米雷耶·吉林斯
罗伯特·古德诺
柯蒂斯·泰里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huya Biological International Co ltd
Huya Bioscience International LLC
Original Assignee
Huya Biological International Co ltd
Huya Bioscience International LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huya Biological International Co ltd, Huya Bioscience International LLC filed Critical Huya Biological International Co ltd
Priority to CN202211089980.8A priority Critical patent/CN115385871A/zh
Publication of CN112638903A publication Critical patent/CN112638903A/zh
Application granted granted Critical
Publication of CN112638903B publication Critical patent/CN112638903B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/32—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of salts of sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/05—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing at least two sulfo groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Materials Engineering (AREA)
  • Polymers & Plastics (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Inorganic Chemistry (AREA)
CN202080004796.1A 2019-01-29 2020-01-28 舒欣啶盐 Active CN112638903B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211089980.8A CN115385871A (zh) 2019-01-29 2020-01-28 舒欣啶盐

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962798467P 2019-01-29 2019-01-29
US62/798,467 2019-01-29
US202062959687P 2020-01-10 2020-01-10
US62/959,687 2020-01-10
PCT/US2020/015370 WO2020159959A1 (en) 2019-01-29 2020-01-28 Sulcardine salts

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202211089980.8A Division CN115385871A (zh) 2019-01-29 2020-01-28 舒欣啶盐

Publications (2)

Publication Number Publication Date
CN112638903A CN112638903A (zh) 2021-04-09
CN112638903B true CN112638903B (zh) 2022-08-26

Family

ID=69724142

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080004796.1A Active CN112638903B (zh) 2019-01-29 2020-01-28 舒欣啶盐
CN202211089980.8A Pending CN115385871A (zh) 2019-01-29 2020-01-28 舒欣啶盐

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202211089980.8A Pending CN115385871A (zh) 2019-01-29 2020-01-28 舒欣啶盐

Country Status (16)

Country Link
US (3) US11426382B2 (https=)
EP (1) EP3917921A1 (https=)
JP (3) JP2022518906A (https=)
KR (2) KR102405199B1 (https=)
CN (2) CN112638903B (https=)
AU (1) AU2020216925B2 (https=)
BR (1) BR112021014640A8 (https=)
CA (1) CA3128152A1 (https=)
CL (1) CL2021001968A1 (https=)
CO (1) CO2021011042A2 (https=)
IL (1) IL285184B2 (https=)
MX (2) MX2021009033A (https=)
PH (1) PH12021551818A1 (https=)
SG (1) SG11202108160YA (https=)
WO (1) WO2020159959A1 (https=)
ZA (2) ZA202105344B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts
IL298907A (en) * 2020-06-12 2023-02-01 Huyabio Int Llc Administering sulcardin for the treatment of acute atrial fibrillation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299813A (zh) * 1999-12-10 2001-06-20 中国科学院上海药物研究所 N－取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US20120309810A1 (en) * 2009-11-17 2012-12-06 HUYA Bioscience International Treatment of atrial fibrillation
CN102869357A (zh) * 2009-11-17 2013-01-09 沪亚生物国际有限责任公司 舒欣啶及其盐的缓慢滴注

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299813C (zh) 2004-12-28 2007-02-14 华南理工大学 自动撕膜落料及多样性搅拌的机构和控制装置
MA41599A (fr) * 2015-02-26 2018-01-02 Array Biopharma Inc Formes cristallines d'un composé pyrrolopyridine
AU2016272089B2 (en) 2015-06-03 2021-02-18 Triastek, Inc. Dosage forms and use thereof
AU2017261372B2 (en) 2016-05-05 2019-02-14 Triastek, Inc. Controlled release dosage form
EP3573602A4 (en) 2017-01-26 2020-09-16 Triastek, Inc. DOSAGE FORMS OF CONTROLLED RELEASE AT SPECIFIC GASTROINTESTINAL SITES
AU2018224136B2 (en) * 2017-02-24 2021-10-21 Gilead Sciences, Inc. Inhibitors of Bruton's Tyrosine Kinase
CN113453677A (zh) 2018-12-13 2021-09-28 沪亚生物国际有限责任公司 用于治疗急性心房颤动的舒卡定施用
SG11202108160YA (en) * 2019-01-29 2021-08-30 Huya Bioscience International Llc Sulcardine salts

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1299813A (zh) * 1999-12-10 2001-06-20 中国科学院上海药物研究所 N－取代苄基或苯基芳香磺酰胺化合物及其用途
CN1939298A (zh) * 2005-09-29 2007-04-04 中国科学院上海药物研究所 硫酸舒欣啶固体和靶向制剂及其制备方法
US20120309810A1 (en) * 2009-11-17 2012-12-06 HUYA Bioscience International Treatment of atrial fibrillation
CN102869357A (zh) * 2009-11-17 2013-01-09 沪亚生物国际有限责任公司 舒欣啶及其盐的缓慢滴注

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
characteristics of hERG and hNav1.5 channel blockade by sulcardine sulfate;chen weihai;《Eupropean Journal of pharmacology》;20181231;第844卷;第130-138页 *
Oral bioavailabiliy and mass balance studies of a novel anti-arrhthmic agent sulcardine sulfate in sprague-Dawley;lu you li;《European journal of drug metabolism and pharmacokinetics》;20161231;第42卷(第3期);第452-459页 *

Also Published As

Publication number Publication date
SG11202108160YA (en) 2021-08-30
CA3128152A1 (en) 2020-08-06
KR20210130157A (ko) 2021-10-29
US20220356319A1 (en) 2022-11-10
CO2021011042A2 (es) 2022-01-17
MX2021009033A (es) 2021-10-13
ZA202107474B (en) 2022-06-29
JP2024039020A (ja) 2024-03-21
EP3917921A1 (en) 2021-12-08
MX2023014776A (es) 2024-01-15
CL2021001968A1 (es) 2022-01-28
BR112021014640A8 (pt) 2022-12-20
JP2025165933A (ja) 2025-11-05
US20210038568A1 (en) 2021-02-11
US11426382B2 (en) 2022-08-30
WO2020159959A1 (en) 2020-08-06
KR102405199B1 (ko) 2022-06-02
AU2020216925A1 (en) 2021-09-02
KR20220079688A (ko) 2022-06-13
ZA202105344B (en) 2023-01-25
AU2020216925B2 (en) 2022-09-15
BR112021014640A2 (pt) 2021-09-21
KR102697726B1 (ko) 2024-08-21
PH12021551818A1 (en) 2022-03-28
IL285184A (en) 2021-09-30
US11020374B2 (en) 2021-06-01
US20250144072A9 (en) 2025-05-08
CN112638903A (zh) 2021-04-09
IL285184B2 (en) 2023-12-01
JP2022518906A (ja) 2022-03-17
IL285184B1 (en) 2023-08-01
US20200316024A1 (en) 2020-10-08
CN115385871A (zh) 2022-11-25

Similar Documents

Publication Publication Date Title
US20220356319A1 (en) Sulcardine salts
AU2019202144A1 (en) Solid forms of {(5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl)amino}acetic acid, compositions, and uses thereof
US20200095203A1 (en) Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl] amino} acetic acid and processes for preparation thereof
TW201720803A (zh) 唾液酸或其鹽或溶劑合物之晶型
JP2023550428A (ja) インテグリン阻害剤およびその使用
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
UA53720C2 (uk) Кислий (2r,3r)-тартрат (r)-3-n,n-дициклоаміно-8-фтор-3,4-дигідро-2н-1-бензопіран-5-карбоксаміду, його моногідрат, спосіб їх одержання та фармацевтична композиція
HK40079384A (en) Sulcardine salts
HK40049638B (en) Sulcardine salts
HK40049638A (en) Sulcardine salts
AU2017342239B2 (en) Crystalline forms of 4-(2-((1R,2R)-2-hydroxycyclohexylamino) benzothiazol-6-yloxy)-N-methylpicolinamide
AU2019344541B2 (en) Erbumine salt of treprostinil
JP2018510173A (ja) トピロキソスタットの新規結晶形及びその製造方法
EA043571B1 (ru) Соли сулькардина
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
BR112015008931B1 (pt) Forma cristalina de (3s,3s) 4,4-disulfanodiilbis(ácido 3-aminobutano 1-sulfônico) de absd; processo para a preparação de uma forma cristalina de absd e l-lisina; e composição farmacêutica
JP2025530060A (ja) 高尿酸血症または痛風を治療若しくは予防するための化合物の固体結晶形
AU2017217728A1 (en) Crystalline modifications of N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine hydrochloride and N-(4,5-bismethanesulfonyl-2-methylbenzoyl)guanidine salts
EA043230B1 (ru) Эрбуминовая соль трепростинила
KR20200096802A (ko) 신장 외수질 칼륨 채널 억제제인 결정 형태 및 이의 제조 방법
KR20210017070A (ko) 신규한 티카그렐러의 결정형, 이의 제조방법 또는 용도
BR112019023592A2 (pt) Formas cristalinas de seletalisibe
BR112019015487A2 (pt) Formas cristalinas de tebipenem pivoxil, composições incluindo as mesmas, métodos de fabricação e métodos de uso
NZ759132B2 (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40049638

Country of ref document: HK

CB02 Change of applicant information
CB02 Change of applicant information

Address after: California, USA

Applicant after: Huya biological International Co.,Ltd.

Address before: California, USA

Applicant before: HUYA BIOSCIENCE INTERNATIONAL LLC

GR01 Patent grant
GR01 Patent grant